Nutriband receives FDA feedback on abuse deterrent fentanyl patch
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- Wall St futures climb as AI stocks rebound; oil, yields fall
- Oil slips from five-month high with Hormuz transits in focus
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Brazil's Bolsonaro, Lula spar in first debate as personal attacks fly
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Micron Technology stock drops on China chip news and labor dispute
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
October 28, 2025 7:00 AM EDTNutriband met with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA FENTANYL (abuse deterrent transdermal system) through commercialization.
Nutriband received final meeting minutes from FDA and is incorporating the feedback into the development program as it moves forward to an IND filing in support of a Human Abuse Potential (HAP) clinical study for the product.
ORLANDO, Fla., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB)(NASDAQ: NTRBW), a company engaged in the development of prescription transdermal... More



